Interventional NIR Fluorescence Imaging of Cancer: Review on Next Generation of Dye-Loaded Protein-Based Nanoparticles for Real-Time Feedback During Cancer Surgery

This article was published in the following Dove Press journal:
International Journal of Nanomedicine

Raluca Borlan^{1,2}
Monica Focsan²
Dana Maniu¹
Simion Astilean^{1,2}

¹Biomolecular Physics Department,
Faculty of Physics, Babeş-Bolyai
University, Cluj-Napoca, Cluj, Romania;
²Nanobiophotonics and Laser
Microspectroscopy Centre,
Interdisciplinary Research Institute in
Bio-Nano-Sciences, Babeş-Bolyai
University, Cluj-Napoca, Cluj, Romania

Abstract: The use of fluorescence imaging technique for visualization, resection and treatment of cancerous tissue, attained plenty of interest once the promise of whole body and deep tissue near-infrared (NIR) imaging emerged. Why is NIR so desired? Contrast agents with optical properties in the NIR spectral range offer an upgrade for the diagnosis and treatment of cancer, by dint of the deep tissue penetration of light in the NIR region of the electromagnetic spectrum, also known as the optical window in biological tissue. Thus, the development of a new generation of NIR emitting and absorbing contrast agents able to overcome the shortcomings of the basic free dye administration is absolutely essential. Several examples of nanoparticles (NPs) have been successfully implemented as carriers for NIR dye molecules to the tumour site owing to their prolonged blood circulation time and enhanced accumulation within the tumour, as well as their increased fluorescence signal relative to free fluorophore emission and active targeting of cancerous cells. Due to their versatile structure, good biocompatibility and capability to efficiently load dyes and bioconjugate with diverse cancer-targeting ligands, the research area of developing protein-based NPs encapsulated or conjugated with NIR dyes is highly promising but still in its infancy. The current review aims to provide an up-to-date overview on the biocompatibility, specific targeting and versatility offered by protein-based NPs loaded with different classes of NIR dyes as next-generation fluorescent agents. Moreover, this study brings to light the newest and most relevant advances involving the state-of-the-art NIR fluorescent agents for the real-time interventional NIR fluorescence imaging of cancer in clinical trials.

Keywords: clinical translation, fluorescent contrast agents, organic nanoparticles, near-infrared dyes

Introduction

Worldwide, cancer is the second leading cause of death, reaching by 2018 the appalling total of 9.6 million deaths.¹ Prevalence of cancer and mortality are rising due to several complex reasons, the basic roots being the aging and growth of the population, together with risk factors related to social and economic development.² The International Agency for Research on Cancer estimated in 2018 that 1 in 5 men and 1 in 6 women develop cancer during their lifespan, while 1 in 8 men and 1 in 11 women unfortunately die of cancer. Although prodigious amounts of research were conducted over the past century to improve the current treatment options of cancer,

Correspondence: Simion Astilean
Email simion.astilean@ubbcluj.ro

Monica Focsan
Email monica.iosin@ubbcluj.ro

no genuine changes were made to the sine qua non of treatment for tumours, namely surgery.³ Wistfully, none of the different imaging modalities used for tumour detection and surgical planning in a preoperative setting, eg computed tomography, positron emission tomography, single-photon emission computed tomography, planar scintigraphy, magnetic resonance imaging, can be translated in the operating theatre due to poor tissue manipulation and mismatched patient position.^{4–6} Moreover, despite the high resolution attained in whole-body imaging, computed tomography has limited specificity in regards to detection of small lesions, less than 10 mm, and the use of ionising radiation must be carried out following strict standard procedures, to avoid the endangerment of surgeons and nurses.^{7,8} Thus, although the high-resolution eyes (50 μm^8) and hands of the surgeon can easily distinguish anatomical structures, during resection it is challenging to differentiate between healthy tissue and malignant lesions ending in the undesired removal of healthy tissue (poor functional outcomes) or an incomplete resection (local recurrence). After surgery, it can take up to 7 days for the pathology report to be sent to the doctor and in the unfortunate event of positive margins, a reintervention is not recommended, the patient being in recovery.^{3,8} Thus,

a new strategy to detect tumours and concomitantly give a real-time feedback during surgery is needed in order to suppress this disease.⁵

Set side-by-side with the classical imaging techniques described above, fluorescence imaging modalities offer high-resolution images, capable of discerning lesions even smaller than 10 μm . The phenomenon of fluorescence is dependent on the nature of the excited state of a molecule or substance, thus when in an excited singlet state (eg after absorption of a photon at a certain wavelength), by pairing the electron in the excited orbital of opposite spin, to a second electron in the ground state orbital, the return to the ground state occurs rapidly, by the emission of a photon at longer wavelengths.⁹ In medicine, fluorescence imaging is a widely used imaging technique for the detection of photons emitted from diseased tissue, after administration of diverse contrast agents of interest. Due to the relatively low costs and flexibility, fluorescence imaging methods are currently being investigated for translation to the operating room, thus improving the resection outcomes and patient lifestyle.^{3,8} Figure 1 depicts the schematic representation of a surgical field set up for cancer patients, injected with a fluorescent agent prior to the surgery, and the fluorescence imaging system

Figure 1 Schematic representation of the surgical field and NIR fluorescence imaging system able to capture in real-time two imaging channels simultaneously.

able to capture in real-time two imaging channels simultaneously; during the surgery, the overlaid image of the two imaging channels is displayed, offering an improved visualisation and detection of malignant tissue. The main disadvantage of visible light fluorescence imaging (eg low tissue penetration and light absorbance by tissue and blood) can be overcome by employing contrast agents in the NIR region of the electromagnetic spectrum.⁵ To outdo the harsh side effects, low photostability and non-specific targeting of standard free dye administration, a multitude of types of NPs have been developed to aptly encapsulate and deliver dyes to the desired type of cancer cells. Among them, protein-based NPs exhibit special interests as they are biodegradable, biocompatible and have a versatile structure.^{10,11}

In this review, we bring to light the recent advancements towards the clinical translation of dye-loaded protein-based NPs as fluorescent agents for the in situ NIR image-guided detection and resection of cancerous tissue. We also aim to provide an up-to-date overview on the biocompatibility, specific targeting and versatility offered by NIR dye loaded protein-based NPs as the next generation of anti-cancer agents and a summarization of the newest and most relevant clinical trials in real-time interventional NIR fluorescence imaging of cancer using state-of-the-art NIR fluorescent agents.

Near-Infrared Dyes Selected for Fluorescence Imaging

The use of dyes that both absorb and emit light in the red and NIR region of the spectrum was the stepping stone to overcome the main drawbacks (eg the absorption by tissue and blood and scattering of light, autofluorescence of tissue) that limited fluorescence imaging in the UV-Vis region to the qualitative surface imaging of only single cell and thin tissue layers. While proteins, melanin, haemoglobin and water have high absorbance coefficients over almost the entire UV-Vis spectrum 200–650 nm,¹² and collagen absorbs at wavelengths over 1450 nm,¹² the tissue penetration of light is highest (up to 2 cm⁸) in the 650–1450 nm range of the electromagnetic spectrum, also known as the optical window in biological tissue. Hence, in the past years, NIR fluorescence imaging and employing NIR fluorophores in pre-clinical research gained mass attention globally.^{5,12} Until today, while fluorophores with emission in a wide range of the electromagnetic spectrum have been approved by the Food and Drug Administration (FDA) for medical purpose,

only two emit light in the NIR region 650–900 nm, namely Indocyanine Green (ICG) and Methylene Blue (MB).^{13,14} Unlike classic small-molecule fluorophores, via the process of restriction of intramolecular motion, aggregation-induced emission luminogens can emit bright NIR light in aggregated states.^{15,16} Thanks to their strong NIR fluorescence and good photobleaching resistance, aggregation-induced emission luminogens recently attained great interest in biomedical applications.^{17,18}

Notwithstanding, organic dyes are still the first option as NIR contrast agents for biomedical imaging, and most of them can be catalogued as squaraines, BODIPY, porphyrins, phthalocyanines or cyanines.^{12,19} Squaraine (squarylium dyes) molecules contain an oxocyclobutenolate core with electron-donating substituents (aromatic or heterocyclic components) at both ends. Squaraines present excellent quantum yields, high absorption coefficients and good photoconductivity, although no significant progress was made in improving water solubility since their first reported synthesis in 1965 by Treibs and Jacob.^{20–22}

BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene – borondipyrromethene dye) were synthesized for the first time in 1968 by (the same) Treibs and Kreuze, and consist of two pyrrole rings linked by a methine bridge, and complexed with a difluoroboron center. Thanks to their good photochemical and thermal stability and excellent quantum yield, the use of BODIPY dyes can be appealing for a wide area of application, such as fluorescent switches, molecular photonic wires or laser dyes; but, despite the numerous attempts in shifting their absorption and emission spectrum to the optical window (NIR region) and as a consequence of their poor water solubility, most of BODIPY dyes are not suited for in vivo fluorescence imaging.^{12,20,21}

Even though the innovative capacity of porphyrin dyes was only upheld later on in history, Hippocrates was the first to notice the negative effect of excess porphyrins in humans. Structurally, porphyrins are a category of aromatic macrocycle organic compounds consisting of four pyrrole subunits linked to each other by methine groups and exist by nature in species, such as heme, cytochromes and chlorophylls. Undeterred by the poor quantum yields and low absorption in the NIR region of simple porphyrins, a small number of more complex porphyrin derivatives were synthesized, displaying promising optical properties for in vivo imaging in the red and NIR region of the spectrum. In addition to their wide applications as a dye, porphyrins are also ideal for molecular materials that can be used in biomedicine, electronics and optoelectronics.^{20,21,23,24}

Phthalocyanines are a group of synthetic dyes containing four isoindole units interconnected by nitrogen atoms, so they form a large ring consisting of 18 π -electrons. These aromatic macrocycle porphyrin derivatives were originally synthesized by happenstance in 1928, but their efficacy as dyes and pigments was established by Linstead in 1934. Owing to their high photostability and good thermal and chemical stability, phthalocyanines have been widely used in fields associated with laser recording materials, chemical sensors, intrinsic semiconductors and are extensively investigated as photoactive chemical compounds in photodynamic therapy. However, phthalocyanines have been overlooked for in vivo imaging considering their poor water solubility, predilection to aggregate and the fact that only a few of them exhibit absorption and emission properties within the optical window in biological tissue.^{19,21,25,26}

The governing fluorophores and gold standard (ICG) of successful in vivo applications continue to belong to the popular family of cyanines (polymethine cyanine dyes) and are defined by two nitrogen atoms connected to each other by a polymethine bridge composed of an odd number of methine units, while each nitrogen atom is contained within an aromatic heterocyclic unit (eg benzoxazole, benzothiazole, indole). The first cyanine dye ever synthesized was described as a blue solid by Williams in 1856 and, since then, these dyes have been used in a broad range of applications from paints to medicinal purposes. Of late, a new generation of cyanine dyes distinguishes by their native tumour targeting capabilities together with good in vivo imaging outcomes, which are heptamethine dyes. On account of their lipophilic cationic nature heptamethine dyes preferentially accumulate in the mitochondria of cancerous cells, giving a great signal-to-noise ratio in tumours compared to healthy tissue sites.^{20,21,27} Table 1 presents the chemical structures and photophysical features of archetypal far-red and NIR fluorophores.

To surmount the shortcomings of administrating free dyes, eg hydrophobicity, aggregation, poor quantum yield and low photostability, an up-and-coming approach is the efficient encapsulation or conjugation of the fluorescent agents (Figure 2) with diverse NPs.^{19,28}

Dye-Loaded Protein-Based Nanoparticles for Interventional NIR Imaging of Cancer – Preclinical Studies

Over the past years, researchers delved into the implementation of NPs as personalized contrast agents for medical imaging, owing to their ability to efficiently load and thus overcome the drawback of using free NIR imaging agents, which predominantly present low photostability, great tendency to aggregate and poor solubility in aqueous solutions.^{11,29} Furthermore, some NPs with diameters in the optimal size range can cross the blood-brain barrier with ease¹¹ and have the capability to accumulate preferentially within tumour microenvironments, either through passive targeting mediated by the enhanced permeability and retention (EPR) effect or via active targeting by bio-conjugation with cancer-specific ligands.^{11,30} On the other hand, in spite of the considerable amount of research carried out for a better understanding of the interplay between synthetic NPs and biological systems, merely a narrow percentage, 2%, reached clinical translation.¹⁰ Thus, an appealing alternative to synthetic NPs is the employment of the versatile, nontoxic and biodegradable protein-based NPs loaded with NIR fluorophores as medical imaging agents.^{10,29}

To date, diverse proteins with plant-based origins (eg gliadin,^{31–33} legumin,³⁴ zein^{35–37}), animal-based origins (eg gelatin,^{38–42} silk,^{43–46} casein,^{47–49} whey,⁵⁰ multimeric enzymes,^{51–53} ferritin,^{54–57} transferrin,^{58–62} albumin^{63–67}) and even virus-derived proteins^{68–72} have been widely used as prime materials for the development of NPs with emerging applications in medicine, but nearly half of them prevail to be studied as NIR fluorescence imaging agents (Figure 3).

The main advantage of NPs synthesized using vegetal proteins over animal-based proteins is probably the low cost of production.¹¹ Zein is a major component of the total protein in corn kernels,³⁵ with a molecular weight of 22–27 kDa.⁷³ Zein proteins have an amphiphilic character³⁷ showing good solubility in alcohol but not in water,³⁵ and are highly used as edible coatings in the food industry.³⁶ Moreover, zein is classified by FDA as a generally regarded as safe (GRAS) excipient for the coating of pills and other pharmaceuticals.⁷³ Thanks to their biodegradability and nontoxic properties, the implementation of zein-based NPs as delivery agents for the control release of anticancer drugs presents promising

Table I Far-Red and NIR Dyes and Their Photophysical Properties

Fluorophore Class	NIR Fluorophore	Chemical Structure	Photophysical Features	Ref.
Squaraine	Iodine-substituted squaraine		λ_{abs} [nm]: 699 ϵ [$\text{M}^{-1} \text{cm}^{-1}$]: 221,000 λ_{em} [nm]: 713 Φ [%]: 58 In dimethylsulfoxide	[26,126]
BODIPY	BODIPY-based ion sensor		λ_{abs} [nm]: 600 λ_{em} [nm]: 656 Φ [%]: 12 In tris hydrochloride	[127,128]
Porphyrin	Chlorin e6		λ_{abs} [nm]: 667 ϵ [$\text{M}^{-1} \text{cm}^{-1}$]: 55,000 λ_{em} [nm]: 668 Φ [%]: 16 In ethanol	[129,130]
Phthalocyanine	Zinc Phthalocyanine		λ_{abs} [nm]: 674 ϵ [$\text{M}^{-1} \text{cm}^{-1}$]: 281,800 λ_{em} [nm]: 678 Φ [%]: 30 In pyridine	[131–133]
Cyanine	IR825		λ_{abs} [nm]: 825 ϵ [$\text{M}^{-1} \text{cm}^{-1}$]: 1.145×10^5 Φ [%]: < 10 In methanol	[134]

results.^{37,73} Gliadin is obtained from wheat and other cereals, being one of the main proteins in the composition of gluten.⁷⁴ It has a molecular mass of 25–100 kDa, with hydrophobic and lightly polar characteristics. Gliadin-based NPs have been previously studied in applications regarding the controlled release and delivery of drugs.⁷³ Another plant-based protein used for the development of NPs is legumin. One of the main advantages of legumin-

based NPs in the biomedical application is their ability to covalently conjugate with diverse biological ligands, via inherent functional groups, for specific delivery and targeting of drugs at desired sites. Legumin is an essential protein present in peas and other leguminous seeds, having an average molecular weight of about 360 kDa.³⁴

Moving forward, proteins derived from milk have also earned consideration as nanocarriers for hydrophobic

Figure 2 Schematic representation of conjugated versus (vs) encapsulated protein-based NPs with NIR emitting fluorophores.

anticancer drugs and other bioactive molecules since they are natural, cheap to manufacture and classified as GRAS.^{48,50} The dominant protein in bovine milk is the flexible casein, with a molecular mass around 19–25 kDa, while β -Lactoglobulin, a small globular molecule with a molecular weight of 18.3 kDa, is the primary whey protein.⁷³ A popular choice as a prime material in the synthesis of organic NPs for drug loading and delivery is

gelatin, due to its biocompatibility, low cost, solubility in aqueous solutions and biodegradable character,⁷⁵ having molecular weights reported between 15 and 400 kDa.⁷⁶ Broadly, gelatin is obtained from type I collagen⁷⁷ found in the bones, tendons, and skins of animals and has long been used in many industries, such as medical, pharmaceutical, cosmetics and food.⁷⁸ As the name suggests, the biological catalysts formally known as enzymes (with

Proteins used in the synthesis of NPs for fluorescence NIR medical imaging:

Proteins used in the synthesis of NPs for other biomedical applications:

Figure 3 Proteins used for the synthesis of NPs loaded with NIR fluorophores for medical imaging (top line) or other biomedical applications (bottom line) and their molecular weights.

Figure 4 In vivo fluorescence imaging of nude mice bearing KB tumors at 1.5 and 4 h after injection of squaraine and BSA adducts and squaraine, BSA and folic acid adducts. Subcutaneous tumours locations are indicated by arrows. Reprinted from *Biomaterials*, 35, Gao FP, Lin YX, Li LL, et al. Supramolecular adducts of squaraine and protein for noninvasive tumor imaging and photothermal therapy in vivo. 1004–1014, copyright (2014), with permission from Elsevier.⁸⁴

reported molecular weight ranging from 14 to 250 kDa^{79,80}), are proteins able to significantly accelerate the rate of chemical reactions in living organisms, without consuming themselves in the process.⁸¹ Enzyme-based NPs attracted a lot of attention as biosensors with enhanced analytical performance and showed high potential as nano agents for delivering cargo.^{82,83}

Although the above-mentioned types of protein-based NPs did not yet receive enough attention as candidates able to incorporate NIR dyes and serve as NIR fluorescence imaging agents, they display great potential for new research in this field.

Squaraine-Loaded Nanoparticles

Up to date albumin remains the cornerstone of protein-based NPs, thanks to its biodegradability, biocompatibility and capacity to bind to a wide range of dyes, drugs, photosensitizers and other bioactive compounds.^{11,75} Albumin is the most abundant of the plasma proteins and for commercial purposes, albumin can be derived from egg white, rat serum, bovine serum (bovine serum albumin (BSA)) and human serum (the FDA approved human serum albumin (HSA)). Considering the similitude between the two heart-shaped proteins BSA (583 amino acids, 69.3 kDa molecular weight) and HSA (585 amino acids, 66.5 kDa molecular weight), a large number of bovine and human albumin-based NPs are currently tested in clinical trials.^{29,75} Albumin-based NPs gained popularity as contrast agents for medical imaging too, since they are able to encapsulate or conjugate to a large spectrum of dyes. One major benefit of loading NIR dyes in albumin-

based NPs is brought to light in the work of Gao et al,⁸⁴ an 80-fold increase in the fluorescence intensity of iodine-substituted squaraine (713 nm free iodine-substituted squaraine emission maximum) after binding to BSA. Gao et al have demonstrated that the enhanced fluorescence intensity of the fluorophore can be associated with the release of the iodine-substituted squaraine molecules from H-aggregates (typically present in free dye solutions) after the addition of BSA, once squaraine and BSA adducts are formed. In the same work, Gao et al performed in vitro and in vivo (Figure 4) studies by the use of squaraine and BSA adducts as fluorescence contrast agents for the NIR imaging of tumours.

Porphyrin-Loaded Nanoparticles

Among with their promising characteristics as agents for photodynamic therapy and photo-thermal therapy, porphyrin-loaded protein-based NPs have been investigated in vitro and in vivo as NIR fluorescence imaging agents for different types of cancers. Battogtokh et al⁸⁵ studied the cellular uptake of free pheophorbide-a (675 nm free pheophorbide-a emission maximum) in comparison with BSA-based NPs loaded with the same fluorophore in B16F10 (murine melanoma) and MCF-7 (human breast adenocarcinoma) cells. Since folate receptors are overexpressed on the surface of these cells, for a targeted delivery the fluorescent BSA-based NPs were conjugated with folic acid. The fluorescence intensity of B16F10 and MCF-7 cells was evaluated using a confocal laser scanning microscope after they were treated for 3 and 6 h with pheophorbide-a-loaded NPs and free pheophorbide-a. In both cases,

Figure 5 In vitro fluorescence imaging of HeLa cells treated for 4 h with folic acid decorated and free BSA-based zinc phthalocyanine loaded NPs. Scale bars represent 50 μ m. Reprinted with permission from Dong C, Liu Z, Wang S, et al. A protein–polymer bioconjugate-coated upconversion nanosystem for simultaneous tumor cell imaging, photodynamic therapy, and chemotherapy. *ACS Appl Mater Interfaces*. 2016;8(48):32688–32698. Copyright (2016) American Chemical Society.⁸⁸

folate targeted NPs showed enhanced fluorescence intensity, and thus a better cellular internalization in comparison with cells treated with free pheophorbide-a. These results are in consonance with the *in vivo* and *ex vivo* assessments, indicating that, in contrast to free pheophorbide-a, folate-targeted pheophorbide-a-loaded BSA-based NPs accumulate preferentially at the tumour site.

Chen et al⁸⁶ and Hu et al⁸⁷ studied the potential of chlorin e6-loaded HSA-based NPs (668 nm free chlorin e6 emission maximum) as fluorescence imaging agents. The *in vitro* and *in vivo* investigations of the fluorescence intensities in U87MG (human primary glioblastoma)⁸⁶ and 4T1 (murine mammary carcinoma)⁸⁷ cells revealed good cellular uptake and accumulation in tumours for the chlorin e6-loaded protein-based NPs. Moreover, by *ex vivo* fluorescence imaging of the tumours Hu et al determined an increase of the fluorescence intensity of almost 1050 times for the mice treated with chlorin e6-loaded protein-based NPs as to free chlorin e6.

Phthalocyanine-Loaded Nanoparticles

A different approach of using BSA in the synthesis of dye loaded NPs for medical imaging and cancer therapy is described in the study conducted by Dong et al.⁸⁸ Dong et al designed a theranostic nanoplatform, loaded with zinc

phthalocyanine fluorophore (678 nm free zinc phthalocyanine emission maximum) and anticancer drug doxorubicin, with upconversion NPs serving as the core of the nanoplatform and a protein (BSA)-polymer shell. *In vitro* studies regarding the fluorescence emission of the zinc phthalocyanine-loaded NPs in HeLa cells (human cervical carcinoma) revealed their capability for real-time image guidance in combined cancer therapy (Figure 5).

Cyanine-Loaded Nanoparticles

Iron ions are used by living cells for a multitude of tasks, eg the transport of oxygen, synthesis of DNA, electron transfer, cell proliferation and metabolism, thus it is no surprise that there are specialized proteins for the storage and transport of iron. Ferritin proteins have a cage-like structure with inner and outer diameters of 8 and 12 nm, respectively, and can accumulate and store, in a bioavailable manner, up to 4500 atoms of iron.⁷⁵ They have a molecular mass of 450 kDa and are abundant in our body, especially in the spleen, liver, bone marrow and skeletal muscle, but not much ferritin can be found in the blood.⁸⁹ Since ferritins are biocompatible, biodegradable and have a hollow structure, they make excellent candidates for a large number of biomedical applications.⁷⁵ Ferritin-based NPs labeled with a NIR

Figure 6 In vitro fluorescence imaging of U87 cells treated for 4 h with free ICG (top) vs transferrin-based ICG loaded NPs (bottom). Reprinted with permission from Zhu M, Sheng Z, Jia Y, et al. Indocyanine green-holo-transferrin nanoassemblies for tumor-targeted dual-modal imaging and photothermal therapy of glioma. *ACS Appl Mater Interfaces*. 2017;9:39249–39258. Copyright year (2017) American Chemical Society.⁹⁴

dye, namely ZW800 (800 nm free ZW800 emission maximum), have been investigated in vitro and in vivo by Zhen et al⁹⁰ as fluorescent contrast agents. Cellular uptake studies have been carried out with U87MG cells (human primary glioblastoma). In vivo and ex vivo fluorescence imaging investigations performed on athymic nude mice subcutaneously injected with the same cell line pointed out good tumour accumulation.

As the name implies, transferrin is the protein responsible for the transport of iron through our body and has a molecular mass of 79 kDa.⁷⁵ Transferrin proteins can carry two atoms of iron(III) and deliver them wherever needed via transferrin receptor-mediated endocytosis.⁹¹ Given that different types of cancer present an overexpression of transferrin receptors on the surface of the cells, targeted delivery of drugs and other therapeutic and imaging agents can be achieved by designing transferrin-based NPs for medical applications.⁷⁵ Kang et al⁹² evaluated in vitro the Cy5.5 loaded transferrin-based NPs (694 nm free Cy5.5 emission maximum) as NIR fluorescence imaging agents with cells known for overexpressing transferrin receptors, eg HeLa (human cervical carcinoma), HT29 (human colorectal adenocarcinoma) and PC3 (human prostate carcinoma) cells. After treatment with transferrin-

based NPs conjugated with Cy5.5 dye, fluorescence signals were detected for all cell lines, while no relevant intranuclear internalization of the NPs was observed. Peng et al⁹³ developed multifunctional transferrin-based NPs conjugated with Cy7 dye (773 nm free Cy7 emission maximum) for targeting, imaging and therapy of cancer. After injection with the Cy7 conjugated NPs, the in vivo fluorescence imaging investigation of nude mice bearing A549 cells (human alveolar epithelial carcinoma) concluded a maximum fluorescence emission at 8 h after the treatment. The in vitro study conducted by Zhu et al⁹⁴ with U87MG cells (human primary glioblastoma) revealed an increase of 2.4-fold of the fluorescence intensity observed after treatment with transferrin-based ICG-loaded NPs in comparison with the fluorescence signal of cells treated with free ICG (830 nm free ICG emission maximum). At 24 h post injection of NPs and free ICG to nude mice bearing U87MG cells, in vivo studies showed an impressive 38-fold increase of the fluorescence signal in the tumour site for the group treated with transferrin-based ICG loaded NPs vs free ICG (Figure 6). Moreover, for mice with orthotopic brain tumours no fluorescence signal was detected when treated with free ICG, in contrast with the transferrin-based NPs treated group that showed the

maximum fluorescence intensity 24 h after injection. These results support their ability to cross the blood-brain barrier and their enhanced targeting and tumour penetration capabilities.

Silk proteins, the products of diverse silkworms, are naturally biodegradable and biocompatible polymeric biomaterials, with a molecular weight of around 83 kD.⁹⁵ Thanks to their auspicious properties against thermal denaturation, dissolution and enzymatic degradation, silk-based NPs can be used as carriers for drugs and other therapeutic agents in biomedical and pharmaceutical applications. Another advantage of silk protein is the abundance of amino acids with functional groups in their structure that facilitate their bioconjugation with various targeting ligands.⁹⁶ Liu et al⁹⁷ investigated in vivo the accumulation at the tumour site of NIR-797 isothiocyanate-loaded silk NPs conjugated with iRGD–EGFR recombinant protein for specific targeting (814 nm free NIR-797 isothiocyanate emission maximum), and a control group without targeting properties. Balb/c (nu/nu) mice subcutaneously injected with HeLa cells (human cervical carcinoma) presented fluorescence signal at the tumour site 4 h post injection with both fluorescent silk-based NPs. However, mice treated with the specific targeting NPs group reached the maximum fluorescence intensity and accumulation at the tumour site 24 h after injection, while the control group achieved maximum fluorescence intensity after 144 h. At 168 h post administration, ex vivo investigations confirmed similar fluorescence signal in the tumour and liver for non-targeting silk NPs, while for the iRGD–EGFR recombinant protein-conjugated silk-based NPs, the fluorescence signal emitted from the liver was lower than that coming from the tumour; no significant fluorescence emission was found in other tissue for both groups of NIR-797 isothiocyanate-loaded silk NPs.

Virus-derived proteins (with molecular weight ranging from 16 to 80 kDa⁶⁸) gained attention as nano agents for their suitable characteristics in a large variety of biological and medical applications, such as diagnosis, therapy and disease prevention.²⁹ Of course, for the manufacture of virus-derived NPs only the noninfectious part of the virus protein is used. Their stability, biocompatibility and their ability to deliver biomolecules, enzymes, drugs, and other bioactive molecules made virus-derived NPs broadly used as nanocarriers and for vaccine design.⁸² Hu et al⁹⁸ studied tobacco mosaic virus-based NPs loaded with the NIR Cy7.5 dye (808 nm free Cy7.5 emission maximum) in vitro with PC3 cells (human prostate carcinoma) and

in vivo in nude mice subcutaneously injected with the same cell line. Since PC3 cells present on their surface an overexpression of $\alpha_2\beta_1$ integrin, the cells and mice were treated with control fluorescent virus-based NPs (non-targeting) and NPs bioconjugated with an Asp-Gly-Glu-Ala peptide for specific targeting. The in vitro investigations revealed a 1.5-fold increase of the fluorescence signal for the cells treated with the targeting NPs, and a fluorescence intensity dependent on the concentration of the NPs administered was observed for cells treated with both targeting and non-targeting virus-based NPs. In vivo studies concluded that maximum accumulation of the fluorescent virus-based NPs in the tumour site occurs 6 h after the injection, measuring a 2.5-fold enhancement in the fluorescence intensity for the group treated with the targeting NPs. The ex vivo fluorescence imaging confirmed the difference in the fluorescence intensity in tumour and other tissues.

Albumin-based NPs have also been investigated for loading NIR cyanine dyes as imaging agents in different kinds of biomedical applications. Cy5-loaded HSA-based NPs conjugated with the photo-activatable Pt(IV) antitumour prodrug (667 nm free Cy5 emission maximum) have been synthesized and studied in vitro by Li et al⁹⁹ with A2780 and A2780 cisplatin-resistant cells (human ovarian carcinoma). The localized activation by UV light irradiation of photoactive Pt(IV) drug within the tumour causes cellular death and generates the activation of caspase 3, leading to the turn-on fluorescence effect of Cy5. In this manner, Li et al archived real-time NIR imaging on controlled drug release together with the assessment of parallel antitumour effects. Chen et al¹⁰⁰ loaded both ICG and Cy5.5 onto HSA-based NPs to investigate the in vitro (Cy5.5 as imaging agent) and in vivo (ICG as imaging agent) cellular internalization and tumour accumulation with MCF-7 cells (human breast adenocarcinoma) and in nude mice subcutaneously injected with MCF-7 cells, respectively. The in vitro imaging investigations demonstrated the colocalization of the fluorescent HSA-based NPs and lysosomes indicating endocytosis as the preferred pathway for cellular uptake of the NPs. The fluorescence intensity of the HSA-based NPs in cells increased over time. The circulation time in vivo of free ICG solution was determined to be up to 8 h, in contrast to the circulation time of ICG when loaded to HSA NPs, even more than 24 h after injection. The maximum fluorescence intensity at the tumour site of the ICG-loaded HSA NPs was measured 8 h after administration. Ex vivo fluorescence imaging

confirmed the increased tumour accumulation of the HSA-based NPs in comparison with other major organs. The *in vitro* cellular uptake and *in vivo* tumour targeting abilities of ICG-loaded albumin-based NPs with MCF-7 cells (human breast adenocarcinoma) have been also studied by Xu et al.¹⁰¹ The cellular internalization of the 100 nm in diameter ICG-loaded BSA NPs has been compared with a group of cells treated with ICG-loaded BSA NPs conjugated with a cell-penetrating peptide (KALA), and a third group of cells treated with ICG-loaded BSA NPs conjugated with KALA and a tumour-targeting aptamer (AS1411). As anticipated, the properties of KALA to destabilize the lipid membrane of cells leads to a more abundant internalization of the NPs, in comparison with cells treated with the nonconjugated fluorescent BSA-based NPs. However, the highest fluorescence signal was measured for the cells treated with ICG-loaded BSA NPs conjugated with KALA and AS1411, thanks to the binding capability of the aptamer with the overexpressed nucleolin in MCF-7 cells. *In vivo* investigations on tumour bearing mice revealed a maximum of the fluorescence intensity at the tumour site 8 h post injection with the ICG-loaded BSA NPs conjugated with KALA and AS1411, and at 24 h after administration, the fluorescence signal remains relatively strong. The *ex vivo* fluorescence imaging of the tumour and other major organs concluded a better accumulation of the ICG-loaded BSA NPs conjugated with KALA and AS1411 in the tumour. Sahu et al.¹⁰² developed 33 nm BSA-based NP loaded with ICG and studied *in vivo* their biodistribution and tumour targeting ability in contrast with free ICG solution, by NIR fluorescence imaging in athymic nude mice subcutaneously injected with SCC7 cells (murine squamous carcinoma). At 3 h after the treatment with free ICG solution, a high fluorescence intensity was observed in the liver of the mice and it slowly decreased over time indicating a short circulation time for free ICG. Also, only a weak fluorescence signal was measured 24 h post injection at the tumour site. In contrast, while a strong fluorescence signal was observed through the whole body at 3 and 6 h post administration of the ICG-loaded BSA NPs, at 12 and 24 h after the injection, in all mice, the highest fluorescence intensity was observed at the tumour site. *Ex vivo* NIR imaging at 24 h post treatments revealed a low fluorescence signal in all major organs and a high accumulation of the ICG-loaded BSA NPs in the tumour, in contrast with tumours from mice treated with free ICG, that

presented a low fluorescence intensity in tumours and higher intensities in other organs, eg liver, lung.

A widely studied NIR contrast agent for the fluorescence imaging of a broad variety of cancer types are the versatile, biocompatible, and biodegradable ICG-loaded HSA NPs. These albumin-based NPs have been designed in different sizes and have been functionalized with various ligands in order to optimize and study *in vivo* and *in vitro* their targeting and delivering performances and offer the possibility of better and personalized treatments in the near future. Chen et al.¹⁰³ and Sheng et al.¹⁰⁴ investigated the *in vivo* tumour accumulation and biodistribution of ICG-loaded HSA NPs intravenously injected into nude mice bearing tumours, after being subcutaneously injected with 4T1 cells (murine mammary carcinoma). Both studies reported a prolonged blood circulation half-life of ICG-loaded HSA NPs compared to the half-life of free ICG, probably mediated by the EPR effect considering the increased sizes of the HSA-based NPs correlated to the size of the free dye molecules. The prolonged half-life of the ICG-loaded HSA NPs is once again brought to light in both studies by the *ex vivo* fluorescence imaging investigations at 24 h after treatments; the ICG accumulation in tumours when loaded onto HSA-based NPs is significantly increased compared to other major organs, as well as in contrast to tumours collected from mice treated with free ICG solution or ICG-HSA complex solution. In addition, Sheng et al considered the *in vitro* cellular uptake of free ICG and ICG-loaded HSA NPs with 4T1 cells. At 3 h after incubation, cells treated with the free ICG solution showed weak fluorescence intensity in parallel with cells treated with the ICG-loaded HSA NPs. The *in vitro* study conducted by Borlan et al¹⁰⁵ on NIH:OVCAR3 cells (human ovarian carcinoma) indicated a good cellular internalization of the ICG loaded HSA NPs via endocytic vesicles 24 h after incubation. The *in vitro* and *in vivo* behaviour of ICG loaded HSA NPs conjugated with folic acid, for the active targeting of the folate receptor alpha present in most HepG2 cells (human hepatocellular carcinoma) was discussed in the work of Yang et al.¹⁰⁶ The *in vitro* investigations concluded a better cellular internalization for the cells treated with the ICG loaded HSA NPs conjugated with folic acid, in comparison with cells treated with free ICG or untargeted fluorescent HSA-based NPs. The *in vivo* fluorescence signal in the tumour site increased over time for mice treated with either free ICG or targeted/untargeted NPs, reaching a maximum fluorescence intensity 24 h after administration. Still, at any tested time

point, the fluorescence intensity for the group treated with targeted HSA-based NPs was greater than that of the other two groups. At 24 h post injection, ex vivo fluorescence imaging of all examined groups related high fluorescence intensities in the liver.

Heptamethine-Loaded Nanoparticles

For a better stability and fluorescence quantum yield than the FDA approved and widely used ICG fluorophore, Rong et al¹⁰⁷ designed a heptamethine CySCOOH dye (840 nm free CySCOOH emission maximum) by the introduction of a rigid cyclohexenyl ring to the heptamethine chain, and covalently conjugated the NIR dye to HSA-based NPs. The in vivo efficiency as NIR imaging agents of CySCOOH-loaded HSA NPs, in parallel with free CySCOOH solution, was investigated in nude mice subcutaneously injected with MCF-7 cells (human breast adenocarcinoma). At only 10 minutes post administration, both tested groups presented fluorescence signal through the whole body, and, in time, an increase of the fluorescence intensity in the tumour site and a decrease of the signal in the whole body was observed for the CySCOOH-loaded HSA NPs group. In time, the mice injected with free CySCOOH solution presented a decrease in the fluorescence signal in the whole body, thus at 1 h post administration, a high percentage of the dye is localized in the spleen and is eliminated from the circulation in less than 24 h. HSA-based NPs have also been complexed with a newly developed NIR dye, with high fluorescence intensity and preferential accumulation within malignant tissue,¹⁰⁸ precisely IR780 iodide (810 nm free IR780 iodide emission maximum), by Han et al.¹⁰⁹ In vitro fluorescence imaging with BxPC-3 cells (human pancreatic carcinoma) confirmed the cellular uptake of the IR780-loaded HSA NPs once the fluorescence intensity in the cytoplasm of the cell enhanced over time. The fluorescence signal of IR780-loaded HSA NPs examined by in vivo NIR imaging on nude mice subcutaneously injected with BxPC-3 cells remained very strong within the tumour even 72 h after administration. IR780-loaded transferrin NPs have been investigated by Wang et al¹¹⁰ with CT26 cells (murine colorectal carcinoma) and the noncancerous L929 cells (murine fibroblast) for control, as imaging agents for specific targeting of cancerous cells due to their ability to bind to the transferrin receptors exposed on the surface of most cancerous cells, in contrast to normal cells. In vitro fluorescence imaging experiments showed an increased fluorescence intensity after an

incubation of 2 h for the CT26 cells treated with IR780-loaded transferrin NPs, compared with the control cells. The in vivo tumour accumulation and biodistribution was evaluated on mice subcutaneously injected with CT26 cells, after the administration of the IR780-loaded transferrin NPs. The fluorescence signal in the tumour site came to a maximum at 48 h after administration. Ex vivo imaging 24 h post injection indicated an enhanced accumulation of the IR780-loaded transferrin NPs in the tumour than in other major organs.

Cohen et al^{111,112} synthesized and loaded a carboxylic acid derivative of the IR783 dye (CANIR) to HSA-based NPs and then covalently conjugated them with diverse ligands (anti-carcinoembryonic antigen antibodies (anti-CEA), peanut agglutinin (PNA)) for the detection of colon tumours (818 nm free CANIR emission maximum). The in vitro cellular uptake and active targeting of CANIR-loaded HSA NPs has been investigated with three different lines of human colorectal adenocarcinoma cells: the CEA overexpressing LS174T cells and HT29 cell line as a control group, with CEA exposed to a significantly lower degree. SW480 cells were used as a control group with low expression of the Thomsen-Friedenreich antigen (PNA binds preferentially to it), an antigen upregulated in numerous colorectal adenocarcinoma cell lines, including LS174T and HT29 cells. The fluorescence intensity of the LS174T cells treated with the CEA targeting CANIR-loaded HSA NPs was above the fluorescence intensity measured for the CEA nontargeting NPs, and 6 times higher in comparison with the control group, the HT29 cells treated with CANIR-loaded HSA NPs conjugated with anti-CEA. Similar performances were observed for LS174T and HT29 cells when treated with CANIR-loaded HSA NPs conjugated with PNA, a much-increased fluorescence intensity (7 times greater) in relation to the fluorescence signal measured for the control SW480 cells after treatment with the same HSA-based NPs. In vivo investigations on Sabra rats with DMH-induced polyps treated with CANIR-loaded HSA NPs conjugated with PNA showed high accumulation of the NPs at the tumour site, measuring a fluorescence intensity 15.5 times higher in comparison with the fluorescence intensity of the surrounding non-cancerous tissue. Nude mice with orthotopic-tumours originate from injection of LS174T cells to the colon wall, were treated with CANIR-loaded HSA NPs conjugated with PNA in order to determine the optimal recovery time between NPs administration and fluorescence imaging of the colon tumours.

Cohen et al concluded that for a good fluorescence signal (of the tumour site) to background (the surrounding non-cancerous tissue) ratio a 4 h recovery time is needed when imaging colorectal cancer.

Over the past few years, the fluorescence imaging properties of IR825 loaded HSA NPs have been studied both in vitro and in vivo in different settings. Chen et al¹¹³ examined with 4T1 cells (murine mammary carcinoma) the in vitro cellular uptake of IR825 loaded HSA NPs and their position relative to lysosomes, indicating a time-dependent internalization mediated by endocytosis. After administrating IR825 loaded HSA NPs to tumour-bearing mice, fluorescence images with good contrast of the tumour site were noticed 1 to 12 h post injection, with the maximum fluorescence signal measured 2 h after the administration of the HSA-based NPs. The good accumulation of the IR825 loaded HSA NPs into the tumour at 2 h after the injection, in comparison with other major organs, was also confirmed by ex vivo fluorescence imaging. The time-dependent cellular internalization of HSA-based NPs loaded with IR825 was also demonstrated in a different study by

Chen et al¹¹⁴ with 4T1 cells (murine mammary carcinoma). When mice subcutaneously injected with 4T1 cells were administered with IR825 loaded HSA NPs, in addition to the expected fluorescence signal measured for the tumour site, the NIR fluorescence imaging investigations revealed a strong fluorescence intensity for the sentinel lymph node nearby the tumour site, reaching a maximum at 30 min post administration. The good accumulation of the IR825 loaded HSA NPs in the sentinel lymph node was also confirmed by ex vivo imaging. Gao et al¹¹⁵ examined the in vitro cellular uptake of IR825 loaded HSA NPs in parallel with free IR825 solution, with A549 cells (human alveolar epithelial carcinoma). At any given incubation time tested, the fluorescence signal of the cells treated with the free IR825 solution was much lower than that of cells treated with the IR825 loaded HSA NPs. These results are confirmed by in vivo fluorescence imaging investigations carried out on tumour bearing mice, after administration with free IR825 solution and IR825 loaded HSA NPs. The control group treated with free IR825 showed low fluorescence intensity in the tumour site,

Table 2 Features and Use of Protein-Based NP Loaded with Squaraine, Porphyrin and Phthalocyanine NIR Dyes for Interventional Fluorescence Imaging of Cancer in Preclinical Studies

Fluorophore Class	NIR Fluorophore	Emission Maximum (nm)	Protein	Size (nm)	In vitro NIR Imaging Cell Line	Preclinical in vivo (ex vivo) NIR Imaging Model	Preclinical in vivo (ex vivo) Imaging Setup	Ref.
Squaraine	Iodine-substituted squaraine	713 ¹²⁶	BSA	11	KB	Female Balb/c nude mice subcutaneously injected with KB cells	680 nm excitation; Maestro in vivo imaging system	[84]
Porphyrin	Pheophorbide-a	675 ¹³⁵	BSA	182	BI6F10 and MCF-7	Balb/c athymic nude mice subcutaneously injected with MCF-7 cells	605–720 nm emission filter; IVIS optical imaging system	[85]
	Chlorin e6	668 ¹³⁰	HSA	50 and 100	U87MG	Female nude mice subcutaneously injected with U87MG cells	661 nm excitation; 700–850 nm emission filter; Maestro in vivo imaging system	[86]
	Chlorin e6	668 ¹³⁰	HSA	100	4T1	Male Balb/c athymic nude mice subcutaneously injected with 4T1 cells	605 nm excitation; 635 nm emission filter; Maestro in vivo imaging system	[87]
Phthalocyanine	Zinc phthalocyanine	678 ¹³³	BSA	45	HeLa	–	–	[88]

Table 3 Features and Use of Protein-Based NP Loaded with Cyanine NIR Dyes for Interventional Fluorescence Imaging of Cancer in Preclinical Studies

Fluorophore Class	NIR Fluorophore	Emission Maximum (nm)	Protein	Size (nm)	In vitro NIR Imaging Cell Line	Preclinical in vivo (ex vivo) NIR Imaging Model	Preclinical in vivo (ex vivo) Imaging Setup	Ref.
Cyanine	ZW800	800	Ferritin	19	U87MG	Athymic nude mice subcutaneously injected with U87MG cells	640–820 nm emission filter; Maestro in vivo imaging system	[90]
	NIR-797 isothiocyanate	814 ¹³⁶	Silk fibroin	138 and 186	–	Balb/c (nu/nu) mice subcutaneously injected with HeLa cells	Maestro in vivo imaging system	[97]
	Cy5	667 ¹³⁷	HSA	200	A2780 and A2780cis	–	–	[99]
	Cy5.5	694 ¹³⁸	Transferrin	–	HeLa, HT29 and PC3	–	–	[92]
	Cy7	773 ¹³⁹	Transferrin	20	–	Male Balb/C nude mice subcutaneously injected with A549 human alveolar epithelial carcinoma cells	720 nm excitation; 790 nm emission filter	[93]
	Cy7.5	808 ¹³⁹	Virus-derived	300x18	PC3	Male athymic nude mice subcutaneously injected with PC3 cells	Cy 7.5 emission filter set; IVIS 200 small-animal imaging system	[98]
	Cy5.5 (in vitro) and ICG (in vivo)	694 ¹³⁸ and 830 ¹⁴⁰	HSA	121	MCF-7	Female Balb/c nude mice subcutaneously injected with MCF-7 cells	745 nm excitation; 820 nm emission filter; IVIS optical imaging system	[100]
	ICG	830 ¹⁴⁰	Transferrin	10	U87MG	Female Balb/c athymic nude mice with orthotopic-tumours and subcutaneously injected with U87MG cells	IVIS optical imaging system	[94]
	ICG	830 ¹⁴⁰	BSA	33	–	Balb/c athymic nude mice subcutaneously injected with SCC7 murine squamous carcinoma cells	IVIS optical imaging system	[102]
	ICG	830 ¹⁴⁰	BSA	116	MCF-7	Female Balb/c nude mouse subcutaneously injected with MCF-7 cells	770 nm excitation; 830 nm emission filter; IVIS optical imaging system	[101]
	ICG	830 ¹⁴⁰	HSA	75	4T1	Athymic nude mice subcutaneously injected with 4T1 cells	704 nm excitation; 735 nm emission filter; Maestro in vivo imaging system	[104]
	ICG	830 ¹⁴⁰	HSA	80	–	Female nude mice subcutaneously injected with 4T1 cells	Maestro in vivo imaging system	[103]
	ICG	830 ¹⁴⁰	HSA	26	NIH: OVCAR3	–	–	[105]
	ICG	830 ¹⁴⁰	HSA	131	HepG2	Balb/c nude mice subcutaneously injected with HepG2 cells	IVIS optical imaging system	[106]

while imaging investigations of the IR825 loaded HSA NPs group indicated a strong fluorescence signal in the tumour after only 1 h post administration, reaching the maximum intensity 18 h post administration. Tables 2–4 summarize the total of protein-based NPs loaded with NIR dyes discussed in section 3, the loaded fluorophore class, protein, size of the NPs and the types of cancer cells targeted for in vitro, in vivo and ex vivo fluorescence imaging.

Clinical Trials Involving the Use of NIR Contrast Agents for Interventional Fluorescence Imaging of Cancer

Despite the impressive number of newly developed NIR fluorescent nanoagents with promising outcomes in pre-clinical studies,^{116,117} most optical agents approved by FDA for fluorescent image-guided cancer surgery in clinical trials are free fluorescent agents (Table 5), typically with small hydrodynamic diameters, poor quantum yields and low photostability. IRDye 800CW is a cyanine dye (794 nm free IRDye 800CW emission maximum¹¹⁸) that received a lot of attention over the past couple of years as an NIR fluorescent agent in numerous clinical studies that evaluate the safety and diagnostic performance or aim to improve the detection of malignant lesions (even premalignant lesions in some cases) during interventional fluorescence imaging of different types of cancer, eg lung cancer (NCT04459065), head and neck cancer (NCT04511078; NCT01987375), oesophageal cancer and Barrett's Oesophagus (NCT02129933; NCT03877601), colorectal cancer (NCT04101292), pituitary carcinoma (NCT04212793) and brain tumour (NCT04085887).

The benefits of using fluorescence imaging for the early detection of oesophageal adenocarcinoma lesions and dysplasia are brought to light in the work of Nagengast et al¹¹⁹ (NCT02129933), bevacizumab-IRDye 800CW being the drug of choice for 14 patients with Barrett's oesophagus. Before undergoing NIR fluorescence molecular endoscopy combined with endoscopic mucosal resection, the two compared administration routes of bevacizumab-IRDye 800CW to patients were systemic or topical tracer administration. Employing IRDye 800CW as a NIR fluorescent agent helped to identify typically challenging to distinguish and flat lesions, while the topical administration procedure enhanced the early detection of oesophageal adenocarcinoma lesions by 33%, with

respect to high-definition narrowband imaging and white-light endoscopy. Moreover, the specimen obtained from the patients in the systemic administration of bevacizumab-IRDye 800CW approach group presented a tumour-to-background ratio (TBR) of 16.7. In the clinical study presented by Rosenthal et al¹²⁰ (NCT01987375), a total of 12 patients with various origins of head and neck cancer received different doses of cetuximab-IRDye 800CW (herein 2.5 mg/m², 25 mg/m² and 62.5 mg/m²). In situ NIR fluorescence imaging of the cancerous tissue revealed a mean TBR of 4.3 for the patients in the 25 mg/m² dose group, and a 5.2 mean TBR for the 62.5 mg/m² dose group. The ex vivo NIR fluorescence imaging and pathology report of the obtained specimen were analysed and compared, confirming a good correlation between the fluorescence intensity of IRDye 800CW and tumour deposition (Figure 7).

The NIR fluorescent drug cRGDY-PEG-Cy5.5-C dots has been investigated for the first time in a clinical trial (NCT02106598) for patients with head and neck melanoma, breast cancer and colorectal cancer. The experimental Cy5.5 dye-labelled particle drug has been injected before or during the surgery around the primary tumour sites, aiming to assess their potential in discriminating between diseased and non-diseased sentinel lymph nodes. The quality of the fluorescence image contrast for the detection of sentinel lymph nodes was considered regarding their measured TBRs. Furthermore, the nodal specimens obtained after the finalization of the neck dissection have been scrutinized ex vivo to calculate the true and false-positive rates for NIR fluorescence cancer imaging and detection.

Another NIR drug, namely OTL-38 (796 nm free OTL-38 emission maximum¹²¹) is a folate analogue ligand conjugated with an NIR indole cyanine-like green dye and has been studied in clinical trials as a fluorescent agent for the NIR image-guided surgery of cancer (lung cancer: NCT04241315, NCT02872701; ovarian cancer: NCT03180307). Hoogstins et al¹²¹ reported the feasibility of the real-time interventional NIR fluorescence imaging procedure using intravenously infused OTL-38 as a fluorescent agent in 12 patients with ovarian cancer prior to the cytoreductive surgery. The NIR fluorescence-based imaging procedure enhanced the detection of malignant lesions beneath the targeted tissue surface (up to 8 mm). During the whole procedure, the average measured TBR was constant, 4.4, and a sum total of 62 lesions were resected and confirmed via histopathology as true

Table 4 Features and Use of Protein-Based NP Loaded with Cyanine – Heptamethine NIR Dyes for Interventional Fluorescence Imaging of Cancer in Preclinical Studies

Fluorophore Class	NIR Fluorophore	Emission Maximum (nm)	Protein	Size (nm)	In vitro NIR Imaging Cell Line	Preclinical in vivo (ex vivo) NIR Imaging Model	Preclinical in vivo (ex vivo) Imaging Setup	Ref.
Cyanine – Heptamethine	CySCOOH	840	HSA	39	–	Athymic nude mice subcutaneously injected with MCF-7 cells	Maestro in vivo imaging system	[107]
	IR780 iodide	810 ¹⁰⁹	Transferrin	65	CT26	Male Balb/c mice subcutaneously injected with CT26 cells	735 nm excitation; 780–900 nm emission filter; IVIS optical imaging system	[110]
	IR780 iodide	810	HSA	6	BxPC-3	Balb/c nude mice subcutaneously injected with BxPC-3 cells	745–785 nm emission filter; Maestro in vivo imaging system	[109]
	IR783 – carboxylic acid derivative	818 ¹¹²	HSA	100	LS174T, HT29 and SW480	Male Sabra rats subcutaneously injected with the carcinogen dimethylhydrazine (DMH) for colon polyp formation	780 nm excitation; 800 nm emission filter; Odyssey infrared imaging system;	[111]
	IR783 – carboxylic acid derivative	818	HSA	100	–	Nude mice with orthotopic-tumours originated from LS174T and HT29 cells	780 nm excitation; 800 nm emission filter; Odyssey infrared imaging system;	[112]
	IR825	–	HSA	8	4T1	Female nude mice subcutaneously injected with 4T1 cells	Maestro in vivo imaging system	[114]
	IR825	–	HSA	29	A549	Nude mice subcutaneously injected with A549 cells	–	[115]
	IR825	–	HSA	5–10	4T1	Female nude mice and Balb/c mice subcutaneously injected with 4T1 cells	600 nm excitation; Maestro in vivo imaging system	[113]

positives. Employing palpation and standard inspection methods alone, only 71% of the resected malignant lesions were detected.

Considering that ICG is one of the only two NIR fluorophores approved by the FDA for human use in a limited number of medical investigations, the imposing number of completed and ongoing interventional NIR

fluorescence imaging clinical trials using ICG as the fluorescent agent is no surprise. Alone or in combination with other contrast agents, in recent years ICG has been the chosen NIR fluorescent agent in clinical studies for the intraoperative imaging and detection of a remarkable variety of cancer types, eg breast cancer (NCT03579979, NCT03619967, NCT02084784, NCT03735680), sentinel

Table 5 The Newest and Most Relevant Clinical Trials That Use Interventional NIR Fluorescent Imaging

NIR Fluorescent Agent	Drug	Condition	Enrolment	Brief Title	National Clinical Trial Number/ Netherlands Trial Registry ID	Start Date	Ref.
IRDye800CW	IRDye800CW-nimotuzumab	Lung cancer.	36	Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery	NCT04459065	August 2020	[141]
	Panitumumab-IRDye800	Head and neck cancer.	25	Phase II Panitumumab-IRDye800 in Head & Neck Cancer	NCT04511078	September 2020	[142]
	Bevacizumab-IRDye800CW	Barrett's oesophagus.	60	Detection of Early Esophageal Cancer by NIR-FME.	NCT03877601	July 2019	[143]
	Bevacizumab-IRDye800CW	Colorectal cancer.	34	Endoscopic Optical Imaging for Precision Oncology Treatment Applied to Colorectal Tumours (Elios-Color-on-Specimen)	NCT04101292	October 2019	[144]
	Bevacizumab-IRDye800CW	Pituitary tumour; Pituitary adenoma; Pituitary macroadenoma.	15	Detection of PitNET Tissue During TSS Using Bevacizumab-800CW	NCT04212793	March 2020	[145]
	Panitumumab-IRDye800	Brain tumour.	12	Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures	NCT04085887	February 2021	[146]
	Cetuximab-IRDye800	Head and neck cancer.	12	Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures	NCT01987375	November 2015	[147]
	Bevacizumab-IRDye800CW	Oesophageal cancer; Dysplasia.	14	VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions	NCT02129933	April 2014	[148]
Cy5.5	Fluorescent cRGDY-PEG-Cy5.5-C dots	Head and neck melanoma; Breast cancer; Colorectal cancer.	105	Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases	NCT02106598	April 2014	[149]
	OTL-38	Lung neoplasms; Lung cancer.	130	Enabling Lung Cancer Identification Using folate Receptor Targeting	NCT04241315	March 2020	[150]
	OTL-38	Ovarian cancer.	178	OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer	NCT03180307	January 2018	[151]
	OTL38	Lung neoplasms; Lung cancer.	110	OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules	NCT02872701	May 2017	[152]

(Continued)

Table 5 (Continued).

NIR Fluorescent Agent	Drug	Condition	Enrolment	Brief Title	National Clinical Trial Number/ Netherlands Trial Registry ID	Start Date	Ref.
ICG	ICG and MB	Sentinel lymph node; Breast cancer.	130	Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG	NCT03579979	May 2018	[153]
	Technetium radiocolloid, ICG and MB	Breast cancer.	40	Sentinel Lymph Node Mapping With Near Infrared Fluorescent Markers	NCT03619967	July 2018	[154]
	ICG and MB	Sentinel lymph node; Breast cancer.	98	Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research	NCT02084784	January 2014	[155]
	ICG	Peritoneal carcinomatosis; Gastric cancer.	120	Intraoperative ICG Fluorescence Imaging for Peritoneal Carcinomatosis Detection	NCT04352894	September 2020	[156]
	ICG	Endometrial cancer; Cervical cancer.	100	Evaluation of Indocyanine Green-guided Systematic Pelvic Lymphadenectomy in Endometrial and Cervical Cancer	NCT04246580	February 2020	[157]
	ICG	Non-small cell lung cancer; Primary neoplasm.	32	Visible Patient™ With Intravascular Indocyanine Green	NCT03953144	September 2020	[158]
	ICG	Rectal cancer.	100	Fluorescent Lymphography-Guided Lymphadenectomy In Laparoscopic Proctectomy	NCT03854890	July 2019	[159]
	ICG	Uveal melanoma liver metastasis.	15	Laparoscopic Near-Infrared Fluorescence Imaging of Hepatic Uveal Melanoma Metastases.	NTR3869	September 2012	[160]
	ICG	Colorectal cancer liver metastasis; Hepatocellular carcinoma.	12	Intra-operative identification of colorectal liver metastasis or hepatocellular carcinoma using indocyanine green near-infrared fluorescence.	NTR2213	February 2010	[161]
	ONM-100	Breast cancer; Head and neck squamous cell carcinoma; Colorectal cancer; Prostate cancer; Ovarian cancer; Urothelial carcinoma; Non-small cell lung cancer.	60	A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer	NCT03735680	August 2019	[162]

Figure 7 Real-time in situ NIR fluorescence imaging with bevacizumab-IRDye 800CW drug and high-definition endoscopy of oesophageal adenocarcinoma lesions. Dysplastic area missed during high-definition narrowband-imaging and white-light endoscopy inspection. Reproduced from Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A. Nagengast VVB, Hartmans E, Garcia-Allende PB, et al. *Gut*. 68(1):7–10. Copyright 2019, with permission from BMJ Publishing Group Ltd.¹¹⁹

lymph nodes (NCT03579979, NCT02084784), peritoneal carcinomatosis and gastric cancer (NCT04352894), endometrial and cervical cancer (NCT04246580), non-small cell lung cancer (NCT03953144, NCT03735680), primary neoplasm (NCT03953144), rectal cancer (NCT03854890), uveal melanoma liver metastasis (NTR3869), colorectal cancer liver metastasis and hepatocellular carcinoma (NTR2213), head and neck squamous cell carcinoma, colorectal cancer, prostate cancer, ovarian cancer, and urothelial carcinoma (NCT03735680). In his work, He et al¹²² (NCT02084784) examines the safety and efficacy of using ICG for the real-time NIR fluorescence-guided sentinel lymph node biopsy of breast cancer in 98 female patients, as to the standard-of-care blue dye method, using MB staining. Patients received MB and ICG injections before the start of the surgery, offering the possibility to detect by percutaneous fluorescence imaging the lymphatic drainage and potential nodes prior to incision. Thus, the administration of ICG gave the patients the advantage of minimal incision, higher tissue penetration, enhanced detection rate (99% using the ICG method vs 92% for MB) and precise resection of the malignant tissue.

In pursuance of better retention of the drug of interest at the tumour site and higher quantum yields, a number of clinical trials in interventional NIR fluorescence imaging focus their attention on the binding of ICG with HSA molecules (ICG:HSA). In addition to the study presented by He et al,¹²² Troyan et al¹²³ introduced the use of ICG:HSA as the fluorescent agent for the NIR fluorescent mapping of the sentinel lymph nodes during surgery, instead of using free ICG molecules. Due to the increased hydrodynamic diameter of the drug, as a result of the complex of the ICG dye and the 7 nm HSA protein molecules, the ICG:HSA method ensued in better NIR fluorescence contrast and enhanced retention of the fluorescent agent within the sentinel lymph nodes during real-time NIR image-guided surgery of cancer. In another clinical study, Verbeek et al¹²⁴ compared the use of free ICG vs ICG:HSA as optical agents for NIR fluorescent sentinel lymph node mapping (Figure 8) in 36 patients with vulvar cancer. The use of the ICG:HSA complex turned out to be 25% more efficient in detecting sentinel lymph nodes during real-time interventional NIR fluorescence imaging, as to the use of free ICG.

Figure 8 Real-time in situ NIR fluorescence imaging with ICG as the contrast agent of sentinel lymph nodes in vulvar cancer patients. Reproduced from Sentinel lymph node biopsy in vulvar cancer using combined radioactive and fluorescence guidance. Verbeek FPR, Tummers QRJG, Rietbergen DDD, et al. *Int J Gynecol Cancer*. 25:1086–1093. Copyright (2015), with permission from BMJ Publishing Group Ltd.¹²⁴

At last, the emerging need of implementing in clinical trials a new generation of fluorescent agents for a better intratumoural internalization of the drug of interest and higher TBRs during surgery, based on the same NIR dyes or new ones, but loaded within nanostructures, such as NPs, is undeniable. Moreover, it is worth bearing in mind that out of over 60 NPs that are now approved by the FDA in clinical trials,¹¹⁷ most of the NPs involved in clinical studies in oncology are organic NPs.¹²⁵ Thus, with diameters in the optimal range (10–300 nm¹⁰⁵) to undergo EPR-mediated passive targeting, a versatile surface chemistry offering the possibility of active targeting of the tumours, and countless preclinical studies proving their biocompatibility and efficiency as fluorescent agents, NIR fluorescent protein-based NPs exhibit bright potential as contrast agents for the real-time NIR fluorescence imaging of cancer in clinical trials.

Conclusions

The top-notch works summarized in this review acknowledge the versatility, biocompatibility and limitless functionalization

possibility of protein-based NPs as the next generation of NIR imaging agents. The encapsulation or conjugation of NIR dyes to diverse protein-based NPs overcame the drawbacks of using free fluorophores for NIR imaging investigations (eg poor photostability and quantum yield, hydrophobicity and aggregation) resulting in impressive enhancement, 80-fold in solution, of the fluorescence intensity of iodine-substituted squaraine dye when loaded onto protein-based NPs, in comparison with the free dye solution. In comparison to mice treated with free ICG, a 38-fold increase in the fluorescence signal was observed in the cancerous tissue of mice treated with protein-based NPs loaded with ICG. Thus, fluorescent protein-based NPs loaded with various NIR dyes present prolonged blood circulation time and enhanced accumulation in the tumour site, thanks to their enlarged size in comparison to free dye molecule and their surface chemistry and ability to bind with specific cancer ligands for an active targeting. The feasibility of NIR fluorescent protein-based NPs as contrast agents for the real-time interventional NIR fluorescence imaging of cancer in clinical trials was demonstrated by

comparison to completed and ongoing clinical trials concerning fluorescent agents for cancer surgery, their biocompatibility being testified by a notable number of preclinical animal studies. Overall, it may be said that NIR dye loaded protein-based NPs have the potential to be translated in the near future as imaging agents for real-time NIR fluorescence-guided cancer surgery.

Acknowledgments

This work was supported by a grant from the Ministry of Research and Innovation, CNCS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0142, within PNCDI III.

Disclosure

The authors report no conflicts of interest in this work.

References

- Copur MS. State of cancer research around the globe. *Oncology (Williston Park, N Y)*. 2019;33(5):181–185.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424. doi:10.3322/caac.21492
- Zhang RR, Schroeder AB, Grudzinski JJ, et al. Beyond the margins: real-time detection of cancer using targeted fluorophores. *Nat Rev Clin Oncol*. 2017;14(6):347–364. doi:10.1038/nrclinonc.2016.212
- van Driel PBAA, van de Giessen M, Boonstra MC, et al. Characterization and evaluation of the artemis camera for fluorescence-guided cancer surgery. *Mol Imaging Biol*. 2015;17(3):413–423. doi:10.1007/s11307-014-0799-z
- Haque A, Faizi MSH Md, Rather JA, Khan MS. Next generation NIR fluorophores for tumor imaging and fluorescence-guided surgery: a review. *Bioorg Med Chem*. 2017;25(7):2017–2034. doi:10.1016/j.bmc.2017.02.061
- Solomon SB, Silverman SG. Imaging in interventional oncology. *Radiology*. 2010;257(3):624–640. doi:10.1148/radiol.10081490
- Paul NS, Ley S, Metser U. Optimal imaging protocols for lung cancer staging. *Radiol Clin North Am*. 2012;50:935–949.
- de Boer E, Harlaar NJ, Taruttis A, et al. Optical innovations in surgery: optical innovations in surgery. *Br J Surg*. 2015;102(2):e56–e72. doi:10.1002/bjs.9713
- Lakowicz JR. *Principles of Fluorescence Spectroscopy*. Boston, MA: Springer US; 1999.
- Sandra F, Khaliq NU, Sunna A, Care A. Developing protein-based nanoparticles as versatile delivery systems for cancer therapy and imaging. *Nanomaterials*. 2019;9(9):1329. doi:10.3390/nano9091329
- Tarhini M, Greige-Gerges H, Elaissari A. Protein-based nanoparticles: from preparation to encapsulation of active molecules. *Int J Pharm*. 2017;522(1–2):172–197. doi:10.1016/j.ijpharm.2017.01.067
- Pansare VJ, Hejazi S, Faenza WJ, Prud'homme RK. Review of long-wavelength optical and NIR imaging materials: contrast agents, fluorophores, and multifunctional nano carriers. *Chem Mater*. 2012;24:812–827. doi:10.1021/cm2028367
- Campu A, Focsan M, Lerouge F, et al. ICG-loaded gold nano-bipyramids with NIR activatable dual PTT-PDT therapeutic potential in melanoma cells. *Colloids Surf B Biointerfaces*. 2020;194:111213. doi:10.1016/j.colsurfb.2020.111213
- van Leeuwen FWB, Hardwick JCH, van Erkel AR. Luminescence-based imaging approaches in the field of interventional molecular imaging. *Radiology*. 2015;276:12–29. doi:10.1148/radiol.2015132698
- Chen C, Ou H, Liu R, Ding D. Regulating the photophysical property of organic/polymer optical agents for promoted cancer phototheranostics. *Adv Mater*. 2020;32:1806331. doi:10.1002/adma.201806331
- Ni X, Zhang X, Duan X, Zheng H-L, Xue X-S, Ding D. Near-infrared afterglow luminescent aggregation-induced emission dots with ultrahigh tumor-to-liver signal ratio for promoted image-guided cancer. *Surg Nano Lett*. 2019;19:318–330. doi:10.1021/acs.nanolett.8b03936
- Chen C, Ni X, Jia S, et al. Massively evoking immunogenic cell death by focused mitochondrial oxidative stress using an AIE luminogen with a twisted molecular structure. *Adv Mater*. 2019;31:1904914. doi:10.1002/adma.201904914
- Chen C, Ni X, Tian H, Liu Q, Guo D, Ding D. Calixarene-based supramolecular AIE dots with highly inhibited nonradiative decay and intersystem crossing for ultrasensitive fluorescence image-guided cancer surgery. *Angew Chem Int Ed*. 2020;59:10008–10012. doi:10.1002/anie.201916430
- Yu J, Zhang X, Hao X, et al. Near-infrared fluorescence imaging using organic dye nanoparticles. *Biomaterials*. 2014;35(10):3356–3364. doi:10.1016/j.biomaterials.2014.01.004
- Luo S, Zhang E, Su Y, Cheng T, Shi C. A review of NIR dyes in cancer targeting and imaging. *Biomaterials*. 2011;32(29):7127–7138. doi:10.1016/j.biomaterials.2011.06.024
- Ptaszek M. Rational design of fluorophores for in vivo applications. *Prog Mol Biol Transl Sci*. 2013;113:59–108.
- Demchenko AP, Callis PR. *Advanced Fluorescence Reporters in Chemistry and Biology I: Fundamentals and Molecular Design*. Heidelberg, New York: Springer; 2010.
- Voswinckel P. A constant source of surprises: acute porphyria. Two cases reported by hippocrates and sigmund freud. *Hist Psychiatry*. 1990;1:159–168. doi:10.1177/0957154X9000100201
- Buschow KHJ. *Encyclopedia of Materials: Science and Technology*. Amsterdam; New York: Elsevier; 2001.
- Anon. *Infrared Absorbing Dyes*. New York: Place of publication not identified: Springer-Verlag; 2013.
- Nalwa HS. *Supramolecular Photosensitive and Electroactive Materials*. San Diego, CA: Academic Press; 2001.
- Sun W, Guo S, Hu C, Fan J, Peng X. Recent development of chemosensors based on cyanine platforms. *Chem Rev*. 2016;116:7768–7817. doi:10.1021/acs.chemrev.6b00001
- Chu L, Wang S, Li K, Xi W, Zhao X, Qian J. Biocompatible near-infrared fluorescent nanoparticles for macro and microscopic in vivo functional bioimaging. *Biomed Opt Express*. 2014;5:4076. doi:10.1364/BOE.5.004076
- Madamsetty VS, Mukherjee A, Mukherjee S. Recent trends of the bio-inspired nanoparticles in cancer theranostics. *Front Pharmacol*. 2019;10:1264. doi:10.3389/fphar.2019.01264
- Wang EC, Wang AZ. Nanoparticles and their applications in cell and molecular biology. *Integr Biol*. 2014;6:9–26. doi:10.1039/c3ib40165k
- Duclairioir C, Nakache E, Marchais H, Orecchioni A-M. Formation of gliadin nanoparticles: influence of the solubility parameter of the protein solvent. *Colloid Polym Sci*. 1998;276:321–327. doi:10.1007/s003960050246
- Pathak Y, Thassu D. *Drug Delivery Nanoparticles Formulation and Characterization*. New York: Informa Healthcare; 2009.

33. Duclairoir C, Orecchioni A-M, Depraetere P, Osterstock F, Nakache E. Evaluation of gliadins nanoparticles as drug delivery systems: a study of three different drugs. *Int J Pharm.* 2003;253:133–144. doi:10.1016/S0378-5173(02)00701-9
34. Irache J. Optimization and in vitro stability of legumin nanoparticles obtained by a coacervation method. *Int J Pharm.* 1995;126(1–2):103–109. doi:10.1016/0378-5173(95)04103-6
35. Podaralla S, Perumal O. Preparation of zein nanoparticles by pH controlled nanoprecipitation. *J Biomed Nanotechnol.* 2010;6:312–317. doi:10.1166/jbn.2010.1137
36. Torres-Giner S, Martinez-Abad A, Ocio MJ, Lagaron JM. Stabilization of a nutraceutical omega-3 fatty acid by encapsulation in ultrathin electrosprayed zein prolamine. *J Food Sci.* 2010;75(6):N69–N79. doi:10.1111/j.1750-3841.2010.01678.x
37. Wang H, Zhu W, Huang Y, Li Z, Jiang Y, Xie Q. Facile encapsulation of hydroxycamptothecin nanocrystals into zein-based nanocomplexes for active targeting in drug delivery and cell imaging. *Acta Biomater.* 2017;61:88–100. doi:10.1016/j.actbio.2017.04.017
38. Jain SK, Gupta Y, Jain A, Saxena AR, Khare P, Jain A. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. *Nanomedicine.* 2008;4(1):41–48. doi:10.1016/j.nano.2007.11.004
39. Gupta AK, Gupta M, Yarwood SJ, Curtis ASG. Effect of cellular uptake of gelatin nanoparticles on adhesion, morphology and cytoskeleton organisation of human fibroblasts. *J Control Release.* 2004;95(2):197–207. doi:10.1016/j.jconrel.2003.11.006
40. Bajpai AK, Choubey J. Design of gelatin nanoparticles as swelling controlled delivery system for chloroquine phosphate. *J Mater Sci Mater Med.* 2006;17:345–358. doi:10.1007/s10856-006-8235-9
41. Lee EJ, Khan SA, Park JK, Lim K-H. Studies on the characteristics of drug-loaded gelatin nanoparticles prepared by nanoprecipitation. *Bioprocess Biosyst Eng.* 2012;35(1–2):297–307. doi:10.1007/s00449-011-0591-2
42. Vandervoort J, Ludwig A. Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use. *Eur J Pharm Biopharm.* 2004;57(2):251–261. doi:10.1016/S0939-6411(03)00187-5
43. Kundu J, Chung Y-I, Kim YH, Tae G, Kundu SC. Silk fibroin nanoparticles for cellular uptake and control release. *Int J Pharm.* 2010;388(1–2):242–250. doi:10.1016/j.ijpharm.2009.12.052
44. Mandal BB, Kundu SC. Self-assembled silk sericin/poloxamer nanoparticles as nanocarriers of hydrophobic and hydrophilic drugs for targeted delivery. *Nanotechnology.* 2009;20(35):355101. doi:10.1088/0957-4484/20/35/355101
45. Lammel AS, Hu X, Park S-H, Kaplan DL, Scheibel TR. Controlling silk fibroin particle features for drug delivery. *Biomaterials.* 2010;31(16):4583–4591. doi:10.1016/j.biomaterials.2010.02.024
46. Khalid A, Mitropoulos AN, Marelli B, Tomljenovic-Hanic S, Omenetto FG. Doxorubicin loaded nanodiamond-silk spheres for fluorescence tracking and controlled drug release. *Biomed Opt Express.* 2016;7(1):132. doi:10.1364/BOE.7.000132
47. Penalva R, Esparza I, Agüeros M, Gonzalez-Navarro CJ, Gonzalez-Ferrero C, Irache JM. Casein nanoparticles as carriers for the oral delivery of folic acid. *Food Hydrocoll.* 2015;44:399–406. doi:10.1016/j.foodhyd.2014.10.004
48. Elzoghby A, Helmy mw, Samy WM, Elgindy NA. Novel ionically crosslinked casein nanoparticles for flutamide delivery: formulation, characterization, and in vivo pharmacokinetics. *IJN.* 2013;8:1721.
49. Pan K, Luo Y, Gan Y, Baek SJ, Zhong Q. pH-driven encapsulation of curcumin in self-assembled casein nanoparticles for enhanced dispersibility and bioactivity. *Soft Matter.* 2014;10(35):6820. doi:10.1039/C4SM00239C
50. López-Rubio A, Lagaron JM. Whey protein capsules obtained through electrospraying for the encapsulation of bioactives. *Innov Food Sci Emerg Technol.* 2012;13:200–206. doi:10.1016/j.ifset.2011.10.012
51. Worsdorfer B, Woycechowsky KJ, Hilvert D. Directed evolution of a protein container. *Science.* 2011;331(6017):589–592. doi:10.1126/science.1199081
52. Sun Q, Chen Q, Blackstock D, Chen W. Post-translational modification of bionanoparticles as a modular platform for biosensor assembly. *ACS Nano.* 2015;9(8):8554–8561. doi:10.1021/acsnano.5b03688
53. Izard T, Aevansson A, Allen MD, et al. Principles of quasi-equivalence and euclidean geometry govern the assembly of cubic and dodecahedral cores of pyruvate dehydrogenase complexes. *Proc Natl Acad Sci.* 1999;96(4):1240–1245. doi:10.1073/pnas.96.4.1240
54. Lee EJ, Lee NK, Kim I-S. Bioengineered protein-based nanocage for drug delivery. *Adv Drug Deliv Rev.* 2016;106:157–171.
55. Bhushan B, Kumar SU, Matai I, Sachdev A, Dubey P, Gopinath P. Ferritin nanocages: a novel platform for biomedical applications. *J Biomed Nanotechnol.* 2014;10(10):2950–2976. doi:10.1166/jbn.2014.1980
56. Zhen Z, Tang W, Chen H, et al. RGD-Modified apoferritin nanoparticles for efficient drug delivery to tumors. *ACS Nano.* 2013;7(6):4830–4837. doi:10.1021/nn305791q
57. Kanwar JR, Kamalapuram SK, Krishnakumar S, Kanwar RK. Multimodal iron oxide (Fe₃O₄)-saturated lactoferrin nanocapsules as nanotheranostics for real-time imaging and breast cancer therapy of claudin-low, triple-negative (ER[−]/PR[−]/HER2[−]). *Nanomedicine.* 2016;11:249–268. doi:10.2217/nnm.15.199
58. Chen M-L, He Y-J, Chen X-W, Wang J-H. Quantum-dot-conjugated graphene as a probe for simultaneous cancer-targeted fluorescent imaging, tracking, and monitoring drug delivery. *Bioconjug Chem.* 2013;24:387–397. doi:10.1021/bc3004809
59. Wang D, Li Y, Tian Z, Cao R, Yang B. Transferrin-conjugated nanodiamond as an intracellular transporter of chemotherapeutic drug and targeting therapy for cancer cells. *Ther Deliv.* 2014;5:511–524. doi:10.4155/tde.14.17
60. Sonali SRP, Singh N, Sharma G, et al. Transferrin liposomes of docetaxel for brain-targeted cancer applications: formulation and brain theranostics. *Drug Deliv.* 2016;23:1261–1271. doi:10.3109/10717544.2016.1162878
61. Wang D, Zhu L, Pu Y, Wang J-X, Chen J-F, Dai L. Transferrin-coated magnetic upconversion nanoparticles for efficient photodynamic therapy with near-infrared irradiation and luminescence bioimaging. *Nanoscale.* 2017;9:11214–11221. doi:10.1039/C7NR03019C
62. Hou L, Shan X, Hao L, Feng Q, Zhang Z. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform. *Acta Biomater.* 2017;54:307–320. doi:10.1016/j.actbio.2017.03.005
63. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. *Expert Opin Pharmacother.* 2006;7:1041–1053. doi:10.1517/14656566.7.8.1041
64. An -F-F, Zhang X-H. Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery. *Theranostics.* 2017;7:3667–3689. doi:10.7150/thno.19365
65. Yu X, Zhu W, Di Y, et al. Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases. *IJN.* 2017;12:6771–6785. doi:10.2147/IJN.S131295
66. Gao L, Fan K, Yan X. Iron oxide nanozyme: a multifunctional enzyme mimetic for biomedical applications. *Theranostics.* 2017;7:3207–3227. doi:10.7150/thno.19738

67. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. *Nat Nanotech.* 2007;2:751–760. doi:10.1038/nnano.2007.387
68. Cardinale D, Carette N, Michon T. Virus scaffolds as enzyme nano-carriers. *Trends Biotechnol.* 2012;30:369–376. doi:10.1016/j.tibtech.2012.04.001
69. Patterson DP, Prevelige PE, Douglas T. Nanoreactors by programmed enzyme encapsulation inside the capsid of the bacteriophage P22. *ACS Nano.* 2012;6:5000–5009. doi:10.1021/nn300545z
70. Koudelka KJ, Pitek AS, Manchester M, Steinmetz NF. Virus-based nanoparticles as versatile nanomachines. *Annu Rev Virol.* 2015;2:379–401. doi:10.1146/annurev-virology-100114-055141
71. Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design: platforms for contemporary vaccine design *WIREs. Nanomed Nanobiotechnol.* 2011;3:174–196. doi:10.1002/wnan.119
72. Yildiz I, Shukla S, Steinmetz NF. Applications of viral nanoparticles in medicine. *Curr Opin Biotechnol.* 2011;22:901–908. doi:10.1016/j.copbio.2011.04.020
73. Elzoghby AO, Elgohary MM, Kamel NM. Implications of protein- and peptide-based nanoparticles as potential vehicles for anticancer drugs. *Adv Protein Chem Struct Biol.* 2015;98:169–221.
74. Freeman HJ. Celiac Disease. In: *Reference Module in Biomedical Sciences.* Elsevier; 2017:B9780128012383000000. Available from: <https://linkinghub.elsevier.com/retrieve/pii/B9780128012383000532>. Accessed March 04, 2021.
75. Gou Y, Miao D, Zhou M, Wang L, Zhou H, Su G. Bio-inspired protein-based nanoformulations for cancer theranostics. *Front Pharmacol.* 2018;9:421. doi:10.3389/fphar.2018.00421
76. Benjakul S, Kittiphattanabawon P. *Gelatin Encyclopedia of Food Chemistry.* Elsevier; 2019:121–127.
77. Smith AM, Moxon S, Morris GA. *Biopolymers as Wound Healing Materials Wound Healing Biomaterials.* Elsevier; 2016:261–287.
78. Alihosseini F. *Plant-Based Compounds for Antimicrobial Textiles Antimicrobial Textiles.* Elsevier; 2016:155–195.
79. Salama BM, Helmy WA, Ragab TIM, Ali MM, Taie HAA, Esawy MA. Characterization of a new efficient low molecular weight *Bacillus subtilis* NRC 16 levansucrase and its levan. *J Basic Microbiol.* 2019;59:1004–1015. doi:10.1002/jobm.201900170
80. Chen Q, Cheng M, Wang Y, et al. A simple method of catalase purification for the undergraduate experimental course. *Mol Med Rep.* 2015;11:1340–1343. doi:10.3892/mmr.2014.2806
81. Pundir CS. *Introduction to Enzyme and Nanotechnology Enzyme Nanoparticles.* Elsevier; 2015:1–7.
82. Raeeszadeh-Sarmazdeh M, Hartzell E, Price JV, Chen W. Protein nanoparticles as multifunctional biocatalysts and health assessment sensors. *Curr Opin Chem Eng.* 2016;13:109–118. doi:10.1016/j.coche.2016.08.016
83. Pundir CS. *Applications of Enzyme Nanoparticles Enzyme Nanoparticles.* Elsevier; 2015:43–60.
84. Gao F-P, Lin Y-X, Li -L-L, et al. Supramolecular adducts of squaraine and protein for noninvasive tumor imaging and photothermal therapy in vivo. *Biomaterials.* 2014;35:1004–1014. doi:10.1016/j.biomaterials.2013.10.039
85. Battogtokh G, Ko YT. Graphene oxide-incorporated pH-responsive folate-albumin-photosensitizer nanocomplex as image-guided dual therapeutics. *J Control Release.* 2016;234:10–20. doi:10.1016/j.jconrel.2016.05.007
86. Chen Q, Wang X, Wang C, Feng L, Li Y, Liu Z. Drug-induced self-assembly of modified albumins as nano-theranostics for tumor-targeted combination therapy. *ACS Nano.* 2015;9:5223–5233. doi:10.1021/acs.nano.5b00640
87. Hu D, Sheng Z, Gao G, et al. Activatable albumin-photosensitizer nanoassemblies for triple-modal imaging and thermal-modulated photodynamic therapy of cancer. *Biomaterials.* 2016;93:10–19. doi:10.1016/j.biomaterials.2016.03.037
88. Dong C, Liu Z, Wang S, et al. A protein–polymer bioconjugate-coated upconversion nanosystem for simultaneous tumor cell imaging, photodynamic therapy, and chemotherapy. *ACS Appl Mater Interfaces.* 2016;8(48):32688–32698. doi:10.1021/acsami.6b11803
89. Aldred E. *Scientific Tests Pharmacology.* Elsevier; 2009:331–341.
90. Zhen Z, Tang W, Guo C, et al. Ferritin nanocages to encapsulate and deliver photosensitizers for efficient photodynamic therapy against cancer. *ACS Nano.* 2013;7(8):6988–6996. doi:10.1021/nn402199g
91. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. *Biochim Biophys Acta.* 1997;1331(1):1–40. doi:10.1016/S0304-4157(96)00014-7
92. Kang CS, Ren S, Sun X, Chong H-S. Theranostic polyaminocarboxylate-cyanine-transferrin conjugate for anticancer therapy and near-infrared optical imaging. *Chem Med Chem.* 2016;11(19):2188–2193. doi:10.1002/cmdc.201600072
93. Peng H, Tang J, Zheng R, et al. Nuclear-targeted multifunctional magnetic nanoparticles for photothermal therapy. *Adv Healthcare Mater.* 2017;6(7):1601289. doi:10.1002/adhm.201601289
94. Zhu M, Sheng Z, Jia Y, et al. Indocyanine green-holo-transferrin nanoassemblies for tumor-targeted dual-modal imaging and photothermal therapy of glioma. *ACS Appl Mater Interfaces.* 2017;9:39249–39258. doi:10.1021/acsami.7b14076
95. Wei W, Zhang Y, Shao H, Hu X. Determination of molecular weight of silk fibroin by non-gel sieving capillary electrophoresis. *J AOAC Int.* 2010;93:1143–1147. doi:10.1093/jaoac/93.4.1143
96. Mottaghtalab F, Farokhi M, Shokrgozar MA, Atyabi F, Hosseinkhani H. Silk fibroin nanoparticle as a novel drug delivery system. *J Control Release.* 2015;206:161–176.
97. Liu B, Wu P, Sha H, et al. Anti-EGFR-irGD recombinant protein conjugated silk fibroin nanoparticles for enhanced tumor targeting and antitumor efficiency. *OTT.* 2016;3153. doi:10.2147/OTT.S100678
98. Hu H, Zhang Y, Shukla S, Gu Y, Yu X, Steinmetz NF. Dysprosium-modified tobacco mosaic virus nanoparticles for ultra-high-field magnetic resonance and near-infrared fluorescence imaging of prostate cancer. *ACS Nano.* 2017;11:9249–9258. doi:10.1021/acs.nano.7b04472
99. Li X, Mu J, Liu F, et al. Human transport protein carrier for controlled photoactivation of antitumor prodrug and real-time intracellular tumor imaging. *Bioconj Chem.* 2015;26:955–961. doi:10.1021/acs.bioconjchem.5b00170
100. Chen S, Yu G, Zhang B, Wang Y, Zhang N, Chen Y. Human serum albumin (HSA) coated liposomal indocyanine green for in vivo tumor imaging. *RSC Adv.* 2016;6(18):15220–15225. doi:10.1039/C5RA25129J
101. Xu L, Wang S-B, Xu C, et al. Multifunctional albumin-based delivery system generated by programmed assembly for tumor-targeted multimodal therapy and imaging. *ACS Appl Mater Interfaces.* 2019;11:38385–38394. doi:10.1021/acsami.9b11263
102. Sahu A, Lee JH, Lee HG, Jeong YY, Tae G. Prussian blue/serum albumin/indocyanine green as a multifunctional nanotheranostic agent for bimodal imaging guided laser mediated combinatorial phototherapy. *J Control Release.* 2016;236:90–99. doi:10.1016/j.jconrel.2016.06.031
103. Chen Q, Liang C, Wang C, Liu Z. An imagable and photothermal “abraxane-like” nanodrug for combination cancer therapy to treat subcutaneous and metastatic breast tumors. *Adv Mater.* 2015;27:903–910. doi:10.1002/adma.201404308
104. Sheng Z, Hu D, Zheng M, et al. Smart human serum albumin-indocyanine green nanoparticles generated by programmed assembly for dual-modal imaging-guided cancer synergistic phototherapy. *ACS Nano.* 2014;8:12310–12322. doi:10.1021/nn5062386

105. Borlan R, Tatar A-S, Soritau O, et al. Design of fluorophore-loaded human serum albumin nanoparticles for specific targeting of NIH: OVCAR3 ovarian cancer cells. *Nanotechnology*. 2020;31:315102. doi:10.1088/1361-6528/ab8b90
106. Yang H, Liu Z, Li X, Zhang Z, Chen D, Lian H. Artesunate-loaded and near-infrared dye-conjugated albumin nanoparticles as high-efficiency tumor-targeted photo-chemo theranostic agent. *Nanoscale Res Lett*. 2018;13:319. doi:10.1186/s11671-018-2700-5
107. Rong P, Huang P, Liu Z, et al. Protein-based photothermal theranostics for imaging-guided cancer therapy. *Nanoscale*. 2015;7(39):16330–16336. doi:10.1039/C5NR04428F
108. Nagy-Simon T, Potara M, Craciun A-M, Licarete E, Astilean S. IR780-dye loaded gold nanoparticles as new near infrared activatable nanotheranostic agents for simultaneous photodynamic and photothermal therapy and intracellular tracking by surface enhanced resonant Raman scattering imaging. *J Colloid Interface Sci*. 2018;517:239–250. doi:10.1016/j.jcis.2018.02.007
109. Han H, Wang J, Chen T, Yin L, Jin Q, Ji J. Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatfrom for pancreatic cancer treatment. *J Colloid Interface Sci*. 2017;507:217–224. doi:10.1016/j.jcis.2017.07.047
110. Wang K, Zhang Y, Wang J, et al. Self-assembled IR780-loaded transferrin nanoparticles as an imaging, targeting and PDT/PTT agent for cancer therapy. *Sci Rep*. 2016;6(1):27421. doi:10.1038/srep27421
111. Cohen S, Pellach M, Kam Y, et al. Synthesis and characterization of near IR fluorescent albumin nanoparticles for optical detection of colon cancer. *Mat Sci Eng C*. 2013;33(2):923–931. doi:10.1016/j.msec.2012.11.022
112. Cohen S, Margel S. Engineering of near IR fluorescent albumin nanoparticles for in vivo detection of colon cancer. *J Nanobiotechnol*. 2012;10(1):36. doi:10.1186/1477-3155-10-36
113. Chen Q, Wang C, Zhan Z, et al. Near-infrared dye bound albumin with separated imaging and therapy wavelength channels for imaging-guided photothermal therapy. *Biomaterials*. 2014;35(28):8206–8214. doi:10.1016/j.biomaterials.2014.06.013
114. Chen Q, Liang C, Wang X, He J, Li Y, Liu Z. An albumin-based theranostic nano-agent for dual-modal imaging guided photothermal therapy to inhibit lymphatic metastasis of cancer post surgery. *Biomaterials*. 2014;35(34):9355–9362. doi:10.1016/j.biomaterials.2014.07.062
115. Gao G, Jiang Y, Sun W, et al. Molecular targeting-mediated mild-temperature photothermal therapy with a smart albumin-based nanodrug. *Small*. 2019;1900501. doi:10.1002/smll.201900501
116. Hong G, Antaris AL, Dai H. Near-infrared fluorophores for biomedical imaging. *Nat Biomed Eng*. 2017;1(1):0010. doi:10.1038/s41551-016-0010
117. Hu Z, Chen W-H, Tian J, Cheng Z. NIRF nanoprobe for cancer molecular imaging: approaching clinic. *Trends Mol Med*. 2020;26(5):469–482. doi:10.1016/j.molmed.2020.02.003
118. LI-COR. IRDye infrared fluorescent dyes deliver enhanced sensitivity. Available from: <https://www.licor.com/bio/reagents/irdye-infrared-dyes>. Accessed March 04, 2021.
119. Nagengast WB, Hartmans E, Garcia-Allende PB, et al. Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A. *Gut*. 2019;68(1):7–10. doi:10.1136/gutjnl-2017-314953
120. Rosenthal EL, Warram JM, de Boer E, et al. Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer. *Clin Cancer Res*. 2015;21(16):3658–3666. doi:10.1158/1078-0432.CCR-14-3284
121. Hoogstins CES, Tummers QRJG, Gaarenstroom KN, et al. A novel tumor-specific agent for intraoperative near-infrared fluorescence imaging: a translational study in healthy volunteers and patients with ovarian cancer. *Clin Cancer Res*. 2016;22:2929–2938. doi:10.1158/1078-0432.CCR-15-2640
122. He K, Chi C, Kou D, et al. Comparison between the indocyanine green fluorescence and blue dye methods for sentinel lymph node biopsy using novel fluorescence image-guided resection equipment in different types of hospitals. *Transl Res*. 2016;178:74–80. doi:10.1016/j.trsl.2016.07.010
123. Troyan SL, Kianzad V, Gibbs-Strauss SL, et al. The FLARE™ intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. *Ann Surg Oncol*. 2009;16:2943–2952. doi:10.1245/s10434-009-0594-2
124. Verbeek FPR, Tummers QRJG, Rietbergen DDD, et al. Sentinel lymph node biopsy in vulvar cancer using combined radioactive and fluorescence guidance. *Int J Gynecol Cancer*. 2015;25:1086–1093. doi:10.1097/JGC.0000000000000419
125. Egloff-Juras C, Bezdetnaya L, Dolivet G, Lassalle H-P. NIR fluorescence-guided tumor surgery: new strategies for the use of indocyanine green. *IJN*. 2019;14:7823–7838. doi:10.2147/IJN.S207486
126. Mayerhöffer U, Fimmel B, Würthner F. Bright near-infrared fluorophores based on squaraines by unexpected halogen effects. *Angew Chem Int Ed*. 2012;51(1):164–167. doi:10.1002/anie.201107176
127. Peng X, Du J, Fan J, et al. A selective fluorescent sensor for imaging Cd²⁺ in living cells. *J Am Chem Soc*. 2007;129:1500–1501. doi:10.1021/ja0643319
128. Ni Y, Wu J. Far-red and near infrared BODIPY dyes: synthesis and applications for fluorescent pH probes and bio-imaging. *Org Biomol Chem*. 2014;12:3774. doi:10.1039/c3ob42554a
129. Nyman ES, Hynninen PH. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. *J Photochem Photobiol B*. 2004;73:1–28. doi:10.1016/j.jphotobiol.2003.10.002
130. Kay A, Humphry-Baker R, Graetzel M. Artificial photosynthesis. 2. Investigations on the mechanism of photosensitization of nanocrystalline TiO₂ solar cells by chlorophyll derivatives. *J Phys Chem*. 1994;98:952–959. doi:10.1021/j100054a035
131. Whalley M. Conjugated macrocycles. Part XXXII. Absorption spectra of tetrazaporphins and phthalocyanines. Formation of pyridine salts. *J Chem Soc*. 1961;182:866. doi:10.1039/jr9610000866
132. Seybold PG, Gouterman M. Porphyrins. *J Mol Spectrosc*. 1969;31:1–13. doi:10.1016/0022-2852(69)90335-X
133. omicron.org. Zinc phthalocyanine, [ZnPc]. Available from: <https://omicron.org/spectra/PhotochemCAD/html/026.html>. Accessed February 23, 2021.
134. Dai Z. *Advances in Nanotheranostics I*. Vol. 6. Dai Z, editor. Berlin, Heidelberg: Springer Series in Biomaterials Science and Engineering; 2016.
135. Eichwurz I, Stiel H, Röder B. Photophysical studies of the pheophorbide a dimer. *J Photochem Photobiol B*. 2000;54:194–200. doi:10.1016/S1011-1344(00)00016-6
136. Tang Q, An Y, Liu D, Liu P, Zhang D. Folate/NIR 797-conjugated albumin magnetic nanospheres: synthesis, characterisation, and in vitro and in vivo targeting evaluation. *PLoS One*. 2014;9(9):e106483. doi:10.1371/journal.pone.0106483
137. Schuler B, Pannell LK. Specific labeling of polypeptides at amino-terminal cysteine residues using Cy5-benzyl thioester. *Bioconjug Chem*. 2002;13:1039–1043. doi:10.1021/bc025509t

138. Chen K, Yap L-P, Park R, et al. A Cy5.5-labeled phage-displayed peptide probe for near-infrared fluorescence imaging of tumor vasculature in living mice. *Amino Acids*. 2012;42:1329–1337. doi:10.1007/s00726-010-0827-5
139. Harbater O, Efrati M, Gannot I. Quantification of two fluorophores' concentration ratio in a mice model in preparation for a proposed method for early detection of alzheimer's disease. *Appl Sci*. 2018;8:745. doi:10.3390/app8050745
140. Zhu S, Yung BC, Chandra S, Niu G, Antaris AL, Chen X. Near-Infrared-II (NIR-II) bioimaging via off-peak NIR-I fluorescence emission. *Theranostics*. 2018;8:4141–4151. doi:10.7150/thno.27995
141. ClinicalTrials.gov. Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
142. ClinicalTrials.gov. Phase II Pantumumab-IRDye800 in Head & Neck Cancer - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
143. ClinicalTrials.gov. Detection of Early Esophageal Cancer by NIR-FME. - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
144. ClinicalTrials.gov. Endoscopic Optical Imaging for Precision Oncology Treatment Applied to Colorectal Tumours (Elios-Color-on-Specimen) - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
145. ClinicalTrials.gov. Detection of PitNET Tissue During TSS Using Bevacizumab-800CW - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
146. ClinicalTrials.gov. Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
147. ClinicalTrials.gov. Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
148. ClinicalTrials.gov. VEGF-targeted Fluorescence Near-Infrared (NIR) endoscopy in (pre)malignant esophageal lesions (VICE). Available from: <https://clinicaltrials.gov/ct2/show/NCT02129933>. Accessed February 12, 2021.
149. ClinicalTrials.gov. Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
150. ClinicalTrials.gov. ELUCIDATE: Enabling LUNg Cancer IDentification Using folATE Receptor Targeting - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
151. ClinicalTrials.gov. OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
152. ClinicalTrials.gov. OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
153. ClinicalTrials.gov. Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
154. ClinicalTrials.gov. Sentinel Lymph Node Mapping With Near Infrared Fluorescent Markers - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
155. ClinicalTrials.gov. Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
156. ClinicalTrials.gov. Intraoperative ICG Fluorescence Imaging for Peritoneal Carcinomatosis Detection - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
157. ClinicalTrials.gov. Evaluation of Indocyanine Green-guided Systematic Pelvic Lymphadenectomy in Endometrial and Cervical Cancer - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
158. ClinicalTrials.gov. Visible Patient™ With Intravascular Indocyanine Green - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
159. ClinicalTrials.gov. Fluorescent Lymphography-Guided Lymphadenectomy In Laparoscopic Proctectomy - Tabular View. Available from: [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed February 12, 2021.
160. Netherlands Trial Register. Anon NTR Laparoscopic Near-Infrared Fluorescence Imaging of Hepatic Uveal Melanoma Metastases. Available from: <https://www.trialregister.nl/trial/3700>. Accessed February 23, 2021
161. Netherlands Trial Register. Intra-operative identification of colorectal liver metastasis or hepatocellular carcinoma using indocyanine green near infrared fluorescence.. Available from: <https://www.trialregister.nl/trial/2096>. Accessed February 23, 2021.
162. ClinicalTrials.gov. A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer - Tabular View. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT03735680>. Accessed February 12, 2021.

International Journal of Nanomedicine

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-nanomedicine-journal>

Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress